In their most recent podcast, the team at Muscle Owl talk about the latest Spinraza news. The European Medical Agency (EMA) has approved the use of Spinraza for all types of spinal muscular atrophy (SMA), so individual countries can now begin the process of approving the drug for treatment.

MORE: EMA panel recommends approval of Spinraza in Europe.

The approval comes on the heels of phase 3 clinical trial results, which showed that Spinraza can significantly improve muscle function and motor skills in children with type 2 SMA. The news may make insurance companies more willing to pay for the treatment for adults and older children who have type 2 and type 3 SMA. Find out more about this trial here.

MORE: Nine commonly asked questions about Spinraza.

SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.